Atara Biotherapeutics (NASDAQ:ATRA) Earns Buy Rating from Cowen

Share on StockTwits

Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “buy” rating reiterated by analysts at Cowen in a research report issued on Friday, TipRanks reports.

ATRA has been the topic of a number of other research reports. William Blair reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday, May 16th. Roth Capital began coverage on shares of Atara Biotherapeutics in a research note on Friday. They issued a “buy” rating and a $30.00 price target on the stock. BidaskClub upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 10th. ValuEngine cut shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. Finally, Wedbush restated an “outperform” rating on shares of Atara Biotherapeutics in a research note on Wednesday, May 29th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Atara Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $36.50.

Shares of ATRA traded down $0.42 during mid-day trading on Friday, reaching $15.16. The company’s stock had a trading volume of 872,463 shares, compared to its average volume of 608,858. The stock has a market cap of $837.55 million, a PE ratio of -2.88 and a beta of 2.10. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.06. Atara Biotherapeutics has a 52 week low of $11.89 and a 52 week high of $43.95. The company’s fifty day moving average price is $13.71 and its two-hundred day moving average price is $24.97.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.45) by ($0.15). Research analysts anticipate that Atara Biotherapeutics will post -5.71 EPS for the current year.

In other Atara Biotherapeutics news, Director Eric Dobmeier purchased 2,000 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were acquired at an average price of $19.50 per share, for a total transaction of $39,000.00. Following the completion of the purchase, the director now owns 16,000 shares of the company’s stock, valued at $312,000. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 7.00% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its holdings in Atara Biotherapeutics by 5.1% in the first quarter. SG Americas Securities LLC now owns 10,432 shares of the biotechnology company’s stock valued at $415,000 after acquiring an additional 503 shares during the period. Oppenheimer & Co. Inc. raised its stake in shares of Atara Biotherapeutics by 15.2% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 10,132 shares of the biotechnology company’s stock worth $203,000 after buying an additional 1,340 shares during the period. Manchester Capital Management LLC acquired a new position in shares of Atara Biotherapeutics during the 1st quarter worth approximately $56,000. DekaBank Deutsche Girozentrale increased its position in shares of Atara Biotherapeutics by 22.2% during the first quarter. DekaBank Deutsche Girozentrale now owns 8,800 shares of the biotechnology company’s stock worth $356,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Xact Kapitalforvaltning AB increased its position in shares of Atara Biotherapeutics by 37.3% during the first quarter. Xact Kapitalforvaltning AB now owns 8,100 shares of the biotechnology company’s stock worth $322,000 after purchasing an additional 2,200 shares in the last quarter. 91.79% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: How to interpret the current ratio

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Homology Medicines  Upgraded to Buy at ValuEngine
Homology Medicines Upgraded to Buy at ValuEngine
Rand Capital  Cut to “Sell” at ValuEngine
Rand Capital Cut to “Sell” at ValuEngine
ValuEngine Downgrades Lockheed Martin  to Sell
ValuEngine Downgrades Lockheed Martin to Sell
$230.18 Million in Sales Expected for Green Dot Co.  This Quarter
$230.18 Million in Sales Expected for Green Dot Co. This Quarter
Reviewing Chubb  & Progressive
Reviewing Chubb & Progressive
AGEAS/S  versus PETROFAC LTD/ADR  Head to Head Analysis
AGEAS/S versus PETROFAC LTD/ADR Head to Head Analysis


 
© 2006-2019 Zolmax.